Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
42.3M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
29.8M
-
Shares change
-
+7.84M
-
Total reported value, excl. options
-
$529M
-
Value change
-
+$139M
-
Put/Call ratio
-
0.53
-
Number of buys
-
73
-
Number of sells
-
-25
-
Price
-
$17.77
Significant Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) as of Q3 2023
121 filings reported holding TARS - Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q3 2023.
Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.8M shares
of 42.3M outstanding shares and own 70.48% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (2.88M shares), Cormorant Asset Management, LP (2.62M shares), Vivo Capital, LLC (2.26M shares), BlackRock Inc. (2.21M shares), TANG CAPITAL MANAGEMENT LLC (2.14M shares), COWEN AND COMPANY, LLC (1.8M shares), Frazier Life Sciences Management, L.P. (1.79M shares), VANGUARD GROUP INC (1.55M shares), PERCEPTIVE ADVISORS LLC (1.3M shares), and TCG Crossover Management, LLC (1.14M shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.